Latest Publications

Share:

Big pharma firms return to the deal table in H1

Dealmaking activity in the US healthcare sector was robust in H1 2022 in the face of various macroeconomic headwinds. There were US$92.4 billion worth of deals announced in H1 2022. This was a 51 percent decrease from a...more

Pharma and healthcare deliver strong results

Despite the absence of megadeals, M&A in the sector climbed from 2020 levels thanks in part to strong PE and SPAC activity - Healthcare and pharmaceutical deals continued at a robust pace through 2021, registering the...more

Healthcare M&A on track to set new record in 2021

Heightened interest in medical suppliers, contract research organizations and biotech firms resulted in an impressive year for healthcare dealmaking- Dealmaking within the pharma, medical and biotech sector continued from...more

House Bill Mandating User Data Portability and Platform Interoperability Could Impact Digital Companies of All Sizes

On June 24, 2021, H.R. 3849, the Augmenting Compatibility and Competition by Enabling Service Switching Act ("ACCESS Act"), was amended by the Committee on the Judiciary and ordered to be reported to the House of...more

Accelerating change: From smart city to smart society

The COVID-19 pandemic has revealed some of the shortcomings of major cities in times of crisis. As the world searches for ways to make urban areas more resilient, smart city initiatives offer some of the answers. ...more

5 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide